Phase I Comparative Bioavailability Study

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

197

Participants

Timeline

Start Date

October 27, 2008

Primary Completion Date

February 6, 2009

Study Completion Date

March 31, 2025

Conditions
Solid Tumors
Interventions
DRUG

AZD2281

Oral single dose formulation

Trial Locations (10)

2031

Research Site, Randwick

3000

Research Site, Leuven

CH-6500

Research Site, Bellinzona

EH4 2XR

Research Site, Edinburgh

NW1 2PG

Research Site, London

M20 4BX

Research Site, Manchester

NE7 7DN

Research Site, Newcastle upon Tyne

HA6 2RN

Research Site, Northwood

OX3 7LE

Research Site, Oxford

SM2 5PT

Research Site, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY